- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
BCMA in Multiple Myeloma (MM): Principles of Targeting and Current Treatment
BCMA in Multiple Myeloma: Principles of Targeting and Current Treatment. The basic principle of targeted BCMA treatment of Multiple Myeloma (MM).
Abstract: This article reviewed three common treatment modalities against BCMA for the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR) modified T cell therapies, and provide an overview of preliminary clinical data from clinical trials using these therapies, which outline the potential of BCMA-based therapies to improve the prospects for MM treatment.
The basic principle of targeted BCMA treatment of MM
B cell maturation antigen, also known as TNFRSF17 or CD269, is a member of the tumor necrosis factor receptor (TNFR) superfamily [6,7]. BCMA is preferentially expressed by mature B lymphocytes and least expressed in hematopoietic stem cells or non-hematopoietic tissues, and is essential for the survival of long-lived bone marrow plasma cells (PC), but is not necessary for the overall B cell homeostasis [ 9-12].
Biology of BCMA in MM
In preclinical models and humans, the overexpression and activation of BCMA is related to the progression of MM, which makes it an attractive therapeutic target [7,15,16]. Mouse xenografts that induced overexpression of BCMA grew faster than the BCMA negative control.
This overexpression leads to the up-regulation of the canonical and non-canonical nuclear factor kappa B pathways, as well as increased expression of genes essential for survival, growth, adhesion, osteoclast activation, angiogenesis, metastasis, and immunosuppression  .
Additional details about the role of BCMA in B cell biology and MM, including illustrations, can be found in other reviews [18-21].
BCMA as a biomarker for MM diagnosis
Malignant MM PC usually consists of a small part of bone marrow cells, so accurate identification of these cells is important to ensure that the disease is representative . The traditional MM biomarker CD138 is highly specific to PC, but it will quickly disappear from the cell surface when sample analysis is delayed or the sample is frozen . Therefore, additional biomarkers are needed to diagnose or monitor MM.
Compared with normal bone marrow mononuclear cells (BMMC) from healthy donors, BCMA is highly expressed on malignant PCs collected from MM patients, and multiple studies have evaluated whether BCMA markers can be used as a diagnosis, prognosis and/or prediction of liver The value of sclerotherapy response (Table 1) [7,23-28].
Compared with CD138, BCMA is easily found in delayed and frozen MM samples . The level of membrane-bound BCMA can be measured by a variety of techniques (such as flow cytometry, immunohistochemistry), but flow cytometry is more sensitive than immunohistochemistry, although due to different methods, the quantification of BCMA levels in each study May be different [7,23,28].
Interestingly, in patients newly diagnosed with MM and RRMM, malignant PCs will express BCMA mRNA at similar levels, which suggests that BCMA may be a promising therapeutic target in the entire course of MM .
The bispecific antibody construct has been modified to have dual antigen specificity and can promote the cell-to-cell interaction between the patient’s own T cells and malignant cells expressing tumor-specific antigens . As shown in a recent review, several different structures have been used for bispecific antibody constructs studied in tumor clinical trials . The forms of these constructs that have been studied in MM include BiTE® (bispecific T cell adaptor; Amgen) molecules and DuoBody® (Genmab A/S) technology, among others.
The BiTE® molecule is a fusion protein consisting of a single-chain variable fragment m (scFv) with unique antigen specificity (Figure 1) .
DuoBody® bispecific antibody constructs are produced by Fab arm exchange, which uses mutation and recombination at the CH3-CH3 antibody interface to combine heavy and light chain homodimers from two separate mAbs into a single heterodimer Dimer, bispecific antibody structure .
AMG 420 (previously BI 836909) is a BCMA×CD3 BiTE® molecule that has been studied in RRMM patients (Table 2). A data report from the first phase multi-dose extension study (NCT02514239) in humans, under the condition of 400μg/day, the objective response rate (ORR) is 70% (7/10), including 5 MRD negative CR ( That is 50) MRDA negative rate percentage), 1 VGPR and 1 PR [41, 48].
Overall, the median time for any response is 1 month. The severe AEs (SAEs) observed in more than one patient were infections and polyneuropathy (PN). Treatment-related SAEs included 2 cases of grade 3 PN and 1 case of grade 3 edema. Three of the 42 patients in the phase 1 study were observed to have grade 2 or 3 cytokine release syndrome (CRS). AMG 701 is a BiTE® molecule that targets the prolonged half-life of BCMA. It seems to induce effective T cell targeted lysis of BCMA-positive MM cells in vitro  and is in clinical development.
ADCs are monoclonal antibodies that target tumor-associated antigens (TAA) coupled to toxic payloads, such as tubulin polymerization inhibitor monomethyl auristatin F (MMAF), pyrrolobenzodiazepine (PBD) or RNA polymerization Enzyme II inhibitor α-amanitin. Cleavable linker [17, 31, 59, 60].
Once bound to target cells expressing TAA, ADC is internalized and releases a toxic payload to induce DNA damage and cell death (Figure 2) [17, 39, 59]. The cleavable linker is processed by the enzyme in the target cell, and the ADC with the non-cleavable linker requires the degradation of the antibody in the lysosome to release the payload . Currently, an anti-BCMA ADC (GSK2857916) has shown anti-myeloma activity in a phase 1 clinical trial, while others have been studied in preclinical species.
GSK2857916 was studied in a phase 1 clinical trial in patients with progressive MM (NCT02064387), which included dose escalation and expansion (Table 2) [31, 61]. GSK2857916 was infused for 1 hour every 3 weeks, and the ORR during the dose expansion phase was 60% (21/35 patients), including two sCR, three CR, 14 VGPR and two PR.
The total median PFS of these patients was 12.0 months. The most common grade 3 or 4 adverse events (AE) during the dose increase period were thrombocytopenia (34%) and anemia (17%). According to reports, 69% of patients had corneal events, most of which were mild to moderate, with a median duration of 35 days.
GSK2857916 was awarded the title of breakthrough treatment by the U.S. Food and Drug Administration (FDA) in November 2017, and is currently being studied in clinical trials in combination with IMiD therapy for RRMM patients .
Anti-BCMA CAR T cell therapy
Several CAR T cell therapies against BCMA have proven efficacy in early clinical trials (Table 3). Although these CAR T cell constructs have some similarities, they differ in the costimulatory domains used (for example, 4-1BB [33,34,37,72,73], CD28[27,74,75 ], OX40 ), hinge region (eg CD8 [27,34,37]), transmembrane domain (eg CD8 [27,37,76], CD28 [33,74]), used to generate anti-BCMA species of scFv (for example, murine [27,74], human [33,37,73,77], llama ), and the use of modifications to enhance the safety of CAR T cell therapy (for example, truncated Epidermal growth factor receptor [73, 74, 77] or other safety switches ).
bb2121 and bb21217
CAR T cell therapy bb2121 has been studied in RRMM patients with RRMM and BCMA expression ≥50% on malignant cells . ORR was 85% (28/33 patients), of which 45% of patients had experienced CR or sCR, and the median duration of response was 10.9 months. The median PFS was 11.8 months. Among the 16 responders who assessed MRD negative, 100% were MRD negative in 10-4 cells or higher, 94% were MRD negative in 10-5 cells or higher, and 19% were MRD negative in 10–4 cells or higher. It is MRD negative at 6 cells. In contrast, two patients who did not respond to bb2121 were MRD positive one month after the infusion. All 33 patients have experienced AEs, and 97% of them have experienced at least Grade 1 AE ≥3. CRS occurred in 76% of patients, of which 2 patients developed grade 3 CRS. Among the 14 patients with neurotoxicity, one patient had grade 4 neurotoxicity 11 days after the infusion. According to early clinical data, bb2121 was awarded the title of FDA breakthrough therapy at the end of 2017.
Another CAR T cell construct similar to bb2121, namely bb21217, is also under clinical research . These CAR T cells are cultured in vitro in the presence of the phosphoinositide 3-kinase inhibitor bb007 to promote a memory-like phenotype, which is speculated to increase the persistence and efficacy of CAR T cells. Among the seven treated patients, the ORR was 86% (one sCR, three VGPR, and two PR), and through next-generation sequencing, all three evaluable responders were MRD negative. CRS was observed in 62.5% (5/8) of patients, including 1 case of grade 3 CRS with grade 4 encephalopathy and signs of posterior reversible encephalopathy syndrome.
National Institutes of Health
NIH CAR-BCMA has been studied in a phase 1 doseescalscal trial in patients with uniform BCMA expression on PC with assessment of scalability [26, 27]. Among the 16 patients who received 9×106 cells/kg or higher, the ORR was 81% (13/16). Through bone marrow assessment, 2 months after NIH CAR-BCMA infusion, all 11 patients were assessed All patients had MRD-negative diseases by flow cytometry (detection limit, 7×10-6).
The duration of myeloma response ranged from 2 to 51 weeks. Of the 11 MRD-negative patients, 6 continued to respond during the last follow-up before publication. The lower dose (no CRS ≥3) is associated with mild treatment-related toxicity.
However, at the highest dose tested (9×106 cells/kg), CRS-related toxicity is quite high, especially for patients with high tumor burden. Overall, 38% of patients require antihypertensive drugs to support blood pressure reduction.
The nervous system toxicity associated with severe CRS is limited to confusion or delusion, and only one patient experienced encephalopathy and muscle weakness consistent with PN.
FCARH143 is a CAR T cell therapy for human BCMA. It is formulated with a 1:1 ratio of CD4+ and CD8+ CAR T cells for infusion, and expresses truncated non-functional human epidermal growth factor receptor to help identification Transduced T cells . The preliminary results of an ongoing phase 1 clinical trial of RRMM patients showed that FCARH143 treatment was associated with the ORR of 6 evaluable patients at 28 days as 100%, and through immunohistochemistry and flow cytometry, all 6 cases None of the patients detected abnormal bone marrow PCs. Currently, the median (range) follow-up for all patients is 16 (2–26) weeks. 86% of patients experienced CRS grade 2 or lower, and no neurotoxicity was observed.
LCAR-B38M is a dual epitope combined with CAR T cell therapy for two different BCMA epitopes, which was studied in a phase 1 trial of RRMM patients . The ORR of three doses of LCAR-B38M infusion within 7 days was 88% (50/57 cases), including 39 cases of CR, 3 cases of VGPR and 8 cases of PR. The negative rate of MRD was 63% (36/57 cases). ) Assessed by bone marrow flow cytometry), defined as 1 tumor cell in <104 normal cells. At the time of the data cut-off before publication, 20% of patients who achieved PR or higher subsequently progressed with a median PFS of 15 months. The most common ≥ grade 3 adverse events were leukopenia (30%), thrombocytopenia (23%) and elevated aspartate aminotransferase (21%). 90% (51/57) of the patients had experienced any severe CRS, including 4 (7%) patients with CRS ≥3, and one of them had Grade 1 neurotoxicity. In another exploratory trial of LCAR-B38M, 17 RRMM patients were observed in a single site, and its efficacy and safety were similar, regardless of whether LCAR-B38M was administered by three infusions or single infusions[ 79].
JCARH125 is a completely human CAR T cell therapy with a costimulatory domain of 4-1BB, which has been studied in a multicenter phase 1/2 trial in patients with RRMM (EVOLVE) . Among 44 patients treated with a dose of 50, 150, or 450×106 cells, the ORR was 82%, and 48% of the patients achieved VGPR or higher. The condition of some patients improved over time, and on the 29th day after the infusion, through next-generation sequencing (defined as ≤1 tumor cell per 105 normal cells), six of the nine evaluable patients were MRD negative. CRS occurs in 80% of patients, and 9% of patients experience ≥ grade 3 CRS. Neurotoxicity of grade 1 to grade 2 and grade ≥3 occurred in 18 and 7% of patients, respectively.
MCARH171 is a human-derived CAR T cell therapy with a truncated EGFR safety system, which has been studied in a phase 1 dose escalation trial . In 11 patients, the ORR of all tested dose levels was 64%; all five patients who received the higher dose level tested (≥450×106 cells) achieved an objective response. The duration of the response ranged from 17 to 235 days. Three-fifths of the patients received treatment at the highest dose, with a response time of more than 6 months, while two patients continued to respond during the 7.5 and 10-month follow-ups. Grade 1-2 and Grade 3 CRS occurred in 40% and 20% of patients, respectively, and one case of Grade 2 neurotoxicity (encephalopathy) was reported.
CART-BCMA is a CAR T cell therapy with full human scFv with T4-1BB costimulatory domain, which has been studied in a phase 1 open-label study of RRMM patients . Twenty-five patients received treatment in 3 dose groups with different CART-BCMA dose levels and/or co-administration of cyclophosphamide (Table 3). In all 25 patients receiving treatment, the ORR was 48%, and in patients receiving higher dose levels (1-5×108 CART-BCMA cells), the ORR was higher (55%). The median (range) response duration was 124.5 (29-939+) days. Three patients had no progress at the time of the data cutoff, and the median overall survival time of all patients receiving treatment was 502 days. Regardless of the attribution to the study drug, AEs of grade 3 or higher were observed in 96% (24/25) of patients. CRS was observed in 88% of patients (32% of grade 3 or 4), and 32% of patients developed neurotoxicity (including 3 cases of grade 3-4 encephalopathy).
(source:internet, reference only)